Trial Profile
A phase I trial of GWP-42006 in patients with autism spectrum disorders.
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 25 Jan 2017
Price :
$35
*
At a glance
- Drugs Cannabidivarin (Primary)
- Indications Pervasive child development disorders
- Focus Adverse reactions
- 25 Jan 2017 New trial record.